nature.com search

Loading Filters

Showing 1–26 of 26 results

Loading Filters

Amendments and Corrections | 18 April 2017
Erratum: Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment
- ...linked to the following affiliations: A Llerena - 7CICAB Clinical Research Center...
- M M Jukić
- , N Opel
- , J Ström
- , T Carrillo-Roa
- , S Miksys
- , M Novalen
- , A Renblom
- , S C Sim
- , E M Peñas-Lledó
- , P Courtet
- , A Llerena
- , B T Baune
- , D J de Quervain
- , A Papassotiropoulos
- , R F Tyndale
- , E B Binder
- , U Dannlowski
- & M Ingelman-Sundberg
Molecular Psychiatry 22 , 1224–1224

Rights & permissionsfor article Erratum: Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment . Opens in a new window.
Amendments and Corrections | 4 December 2012
Erratum: CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients
- E M Peñas-LLedó
- , H D Trejo
- , P Dorado
- , A Ortega
- , H Jung
- , E Alonso
- , M E G Naranjo
- , M López-López
- & A LLerena
Molecular Psychiatry 18 , 266–266

Rights & permissionsfor article Erratum: CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients . Opens in a new window.
Research | 7 March 2017 | Open
VEGF-related polymorphisms identified by GWAS and risk for major depression
- T Xie
- , M G Stathopoulou
- , F de Andrés
- , G Siest
- , H Murray
- , M Martin
- , J Cobaleda
- , A Delgado
- , J Lamont
- , E Peñas-LIedó
- , A LLerena
- & S Visvikis-Siest
Translational Psychiatry 7 , e1055–e1055

Rights & permissionsfor article VEGF-related polymorphisms identified by GWAS and risk for major depression . Opens in a new window.
Research | 12 April 2016
High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina
- G Moya
- , P Dorado
- , V Ferreiro
- , M E G Naranjo
- , E M Peñas-Lledó
- & A LLerena
The Pharmacogenomics Journal 17 , 378–381

Rights & permissionsfor article High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina . Opens in a new window.
Research | 7 June 2016
High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies
- M E G Naranjo
- , F de Andrés
- , A Delgado
- , J Cobaleda
- , E M Peñas-Lledó
- & A LLerena
The Pharmacogenomics Journal 16 , 485–490

Rights & permissionsfor article High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies . Opens in a new window.
Research | 4 November 2014
High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
- M Apellániz-Ruiz
- , L Inglada-Pérez
- , M E G Naranjo
- , L Sánchez
- , V Mancikova
- , M Currás-Freixes
- , A A de Cubas
- , I Comino-Méndez
- , S Triki
- , A Rebai
- , M Rasool
- , G Moya
- , M Grazina
- , G Opocher
- , A Cascón
- , P Taboada-Echalar
- , M Ingelman-Sundberg
- , A Carracedo
- , M Robledo
- , A Llerena
- & C Rodríguez-Antona
The Pharmacogenomics Journal 15 , 288–292

Rights & permissionsfor article High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme . Opens in a new window.
Research | 30 June 2015
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
- A Ortega-Vázquez
- , P Dorado
- , I Fricke-Galindo
- , H Jung-Cook
- , N Monroy-Jaramillo
- , I E Martínez-Juárez
- , I Familiar-López
- , E Peñas-Lledó
- , A LLerena
- & M López-López
The Pharmacogenomics Journal 16 , 286–292

Rights & permissionsfor article CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy . Opens in a new window.
26 June 2012
CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients
- E M Peñas-LLedó
- , H D Trejo
- , P Dorado
- , A Ortega
- , H Jung
- , E Alonso
- , M E G Naranjo
- , M López-López
- & A LLerena
Molecular Psychiatry 18 , 8–9

Rights & permissionsfor article CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients . Opens in a new window.
Research | 20 August 2013
Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain
- A Llerena
- , M Alvarez
- , P Dorado
- , I González
- , E Peñas-LLedó
- , B Pérez
- , J Cobaleda
- & L R Calzadilla
The Pharmacogenomics Journal 14 , 229–234

Rights & permissionsfor article Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain . Opens in a new window.
Research | 12 August 2014
A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances
- E Peñas-Lledó
- , S Guillaume
- , M E G Naranjo
- , A Delgado
- , I Jaussent
- , H Blasco-Fontecilla
- , P Courtet
- & A LLerena
The Pharmacogenomics Journal 15 , 172–176

Rights & permissionsfor article A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances . Opens in a new window.
Research | 29 January 2013
Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico
- M Sosa-Macías
- , B P Lazalde-Ramos
- , C Galaviz-Hernández
- , H Rangel-Villalobos
- , J Salazar-Flores
- , V M Martínez-Sevilla
- , M L Martínez-Fierro
- , P Dorado
- , M L Wong
- , J Licinio
- & A LLerena
The Pharmacogenomics Journal 13 , 567–572

Rights & permissionsfor article Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico . Opens in a new window.
Research | 29 May 2012
Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms
- P Dorado
- , E López-Torres
- , E M Peñas-LLedó
- , J Martínez-Antón
- & A LLerena
The Pharmacogenomics Journal 13 , 359–361

Rights & permissionsfor article Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms . Opens in a new window.
Research | 26 June 2012
Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6
- N González-Vacarezza
- , F Abad-Santos
- , A Carcas-Sansuan
- , P Dorado
- , E Peñas-LLedó
- , F Estévez-Carrizo
- & A LLerena
The Pharmacogenomics Journal 13 , 452–455

Rights & permissionsfor article Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6 . Opens in a new window.
Research | 29 October 2003
CYP2C9 gene and susceptibility to major depressive disorder
- A LLerena
- , R Berecz
- , P Dorado
- , A P González
- , E M Peñas-LLedó
- & A De la Rubia
The Pharmacogenomics Journal 3 , 300–302

Rights & permissionsfor article CYP2C9 gene and susceptibility to major depressive disorder . Opens in a new window.
26 April 2005
Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education
- D Gurwitz
- , J E Lunshof
- , G Dedoussis
- , C S Flordellis
- , U Fuhr
- , J Kirchheiner
- , J Licinio
- , A Llerena
- , V G Manolopoulos
- , L J Sheffield
- , G Siest
- , F Torricelli
- , V Vasiliou
- & S Wong
The Pharmacogenomics Journal 5 , 221–225

Rights & permissionsfor article Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education . Opens in a new window.
Research | 11 May 2010
CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards
- P Dorado
- , M G Sosa-Macias
- , E M Peñas-LLedó
- , R E Alanis-Bañuelos
- , M-L Wong
- , J Licinio
- , I Lares-Asseff
- & A LLerena
The Pharmacogenomics Journal 11 , 108–112

Rights & permissionsfor article CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards . Opens in a new window.
15 February 2011
High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders
- E M Peñas-Lledó
- , P Dorado
- , Z Agüera
- , M Gratacós
- , X Estivill
- , F Fernández-Aranda
- & A LLerena
Molecular Psychiatry 16 , 691–692

Rights & permissionsfor article High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders . Opens in a new window.
Research | 28 September 2004
Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards
- A LLerena
- , P Dorado
- , F O'Kirwan
- , R Jepson
- , J Licinio
- & M-L Wong
The Pharmacogenomics Journal 4 , 403–406

Rights & permissionsfor article Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards . Opens in a new window.
Research | 28 September 2010
CYP2D6 polymorphism in patients with eating disorders
- E M Peñas-LLedó
- , P Dorado
- , Z Agüera
- , M Gratacós
- , X Estivill
- , F Fernández-Aranda
- & A LLerena
The Pharmacogenomics Journal 12 , 173–175

Rights & permissionsfor article CYP2D6 polymorphism in patients with eating disorders . Opens in a new window.
Research | 3 January 2012 | Open
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population
- B Almoguera
- , R Riveiro-Alvarez
- , J Lopez-Castroman
- , P Dorado
- , C Vaquero-Lorenzo
- , J Fernandez-Piqueras
- , A Llerena
- , F Abad-Santos
- , E Baca-García
- , R Dal-Ré
- & C Ayuso
The Pharmacogenomics Journal 13 , 197–204

Rights & permissionsfor article Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population . Opens in a new window.
Research | 7 December 2010
CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
- A LLerena
- , P Dorado
- , R Ramírez
- , I González
- , M Álvarez
- , E M Peñas-LLedó
- , B Pérez
- & L R Calzadilla
The Pharmacogenomics Journal 12 , 176–183

Rights & permissionsfor article CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans . Opens in a new window.
Research | 27 February 2007
Low frequency of CYP2D6 poor metabolizers among schizophrenia patients
- A LLerena
- , P Dorado
- , E M Peñas-LLedó
- , M C Cáceres
- & A De la Rubia
The Pharmacogenomics Journal 7 , 408–410

Rights & permissionsfor article Low frequency of CYP2D6 poor metabolizers among schizophrenia patients . Opens in a new window.
Research | 7 June 2016
Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes
- S Mas
- , P Gassó
- , A Lafuente
- , M Bioque
- , A Lobo
- , A Gonzàlez-Pinto
- , M S Olmeda
- , I Corripio
- , A Llerena
- , B Cabrera
- , J Saiz-Ruiz
- , M Bernardo
- , Gisela Mezquida
- , Ana Meseguer
- , Enrique García Bernardo
- , Mara Parellada
- , Anna Alonso-Solís
- , Eva Grasa
- , Miryam Hernandez
- , Monica Martinez Cengotitabengoa
- , Fe Barcones
- , Julio Arbej
- , Julio Sanjuan
- , Eduardo J Aguilar
- , Antonio Balbuena
- , Anna Mané
- , Carla Torrent
- , Eduard Vieta
- , Immaculada Baeza
- , Elena de la Serna
- , Fernando Contreras
- , Auria Albacete
- , Maria Paz García-Portilla
- , Julio Bobes
- , Arantzazu Zabala Rabadán
- , Rafael Segarra Echevarría
- , Isabel Morales-Muñoz
- , Roberto Rodriguez-Jimenez
- , Anna Butjosa
- , Judith Usall Rodie
- , Salvador Sarró
- , Ramón Landín-Romero
- , Angela Ibañez Cuadrado
- , Manuel J Cuesta
- & Vicent Balanzá-Martínez
The Pharmacogenomics Journal 16 , 439–445

Rights & permissionsfor article Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes . Opens in a new window.
Research | 29 November 2016
Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment
- M M Jukić
- , N Opel
- , J Ström
- , T Carrillo-Roa
- , S Miksys
- , M Novalen
- , A Renblom
- , S C Sim
- , E M Peñas-Lledó
- , P Courtet
- , A Llerena
- , B T Baune
- , D J de Quervain
- , A Papassotiropoulos
- , R F Tyndale
- , E B Binder
- , U Dannlowski
- & M Ingelman-Sundberg
Molecular Psychiatry 22 , 1155–1163

Rights & permissionsfor article Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment . Opens in a new window.
27 October 2015
Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations
- I Fricke-Galindo
- , C Céspedes-Garro
- , F Rodrigues-Soares
- , M E G Naranjo
- , Á Delgado
- , F de Andrés
- , M López-López
- , E Peñas-Lledó
- & A LLerena
The Pharmacogenomics Journal 16 , 113–123

Rights & permissionsfor article Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations . Opens in a new window.
Reviews | 24 February 2015
Pharmacogenomic information in drug labels: European Medicines Agency perspective
- F Ehmann
- , L Caneva
- , K Prasad
- , M Paulmichl
- , M Maliepaard
- , A Llerena
- , M Ingelman-Sundberg
- & M Papaluca-Amati
The Pharmacogenomics Journal 15 , 201–210

Rights & permissionsfor article Pharmacogenomic information in drug labels: European Medicines Agency perspective . Opens in a new window.

Refine your results by…

Filters

Filter By:

Erratum: Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment

Erratum: CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients

VEGF-related polymorphisms identified by GWAS and risk for major depression

High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina

High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies

High frequency and founder effect of the CYP3A420* loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme

CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy

CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients

Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain

A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances

Influence of admixture components on CYP2C92* allele frequency in eight indigenous populations from Northwest Mexico

Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms

Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6

CYP2C9 gene and susceptibility to major depressive disorder

Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education

CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards

High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders

Lower frequency of CYP2C92* in Mexican-Americans compared to Spaniards

CYP2D6 polymorphism in patients with eating disorders

Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population

CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans

Low frequency of CYP2D6 poor metabolizers among schizophrenia patients

Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes

Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment

Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations

Pharmacogenomic information in drug labels: European Medicines Agency perspective

Quick links

Refine your results by…

Filters ​

Filter By:

Search

Quick links

Filters